Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: Multinational phase II-III trial results Academic Article uri icon

Overview

MeSH Major

  • Anticarcinogenic Agents
  • Lymphoma, T-Cell, Cutaneous
  • Tetrahydronaphthalenes

abstract

  • Bexarotene is the first in a novel class of pharmacologic agents, the RXR-selective retinoids, or rexinoids. Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL.

publication date

  • May 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11331325

Additional Document Info

start page

  • 2456

end page

  • 71

volume

  • 19

number

  • 9